ES2192205T3 - Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero. - Google Patents

Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.

Info

Publication number
ES2192205T3
ES2192205T3 ES95932094T ES95932094T ES2192205T3 ES 2192205 T3 ES2192205 T3 ES 2192205T3 ES 95932094 T ES95932094 T ES 95932094T ES 95932094 T ES95932094 T ES 95932094T ES 2192205 T3 ES2192205 T3 ES 2192205T3
Authority
ES
Spain
Prior art keywords
activity
control
inflammation
hemooxigenasa
mammer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932094T
Other languages
English (en)
Inventor
Dean Willis
Adrian Richard Moore
Derek Albert Willoughby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Negma Lerads SA
Original Assignee
Negma Lerads SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4154382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2192205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Negma Lerads SA filed Critical Negma Lerads SA
Application granted granted Critical
Publication of ES2192205T3 publication Critical patent/ES2192205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Rear-View Mirror Devices That Are Mounted On The Exterior Of The Vehicle (AREA)
  • Mirrors, Picture Frames, Photograph Stands, And Related Fastening Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE CONSIGUE CONTROLAR LA INFLAMACION MEDIANTE EL CONTROL DEL NIVEL Y/O ACTIVIDAD DE LA ENZIMA HEMO-OXIGENASA (HO). EL INDUCTOR HO ES ANTIINFLAMATORIO (DIBUJO 14) Y SE UTILIZA PARA TRATAR INFLAMACIONES COMO PUEDEN SER LAS ENFERMEDADES INFLAMATORIAS CRONICAS. EL INHIBIDOR HO FAVORECE LA INFLAMACION Y SE UTILIZA PARA TRATAR AFECCIONES DE INMUNOSUPRESION. DE FORMA ALTERNATIVA, O ADICIONAL, SE CONSIGUE EL CONTROL DE LA ACTIVIDAD DE LA HEMOOXIGENASA MEDIANTE EL CONTROL DE LOS NIVELES DE OXIDO NITRICO, YA QUE LOS NIVELES ELEVADOS FAVORECEN LA INFLAMACION.
ES95932094T 1994-09-22 1995-09-22 Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero. Expired - Lifetime ES2192205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002132690A CA2132690A1 (en) 1994-09-22 1994-09-22 Control and modulation of inflammatory response in humans in need of such control and modulation

Publications (1)

Publication Number Publication Date
ES2192205T3 true ES2192205T3 (es) 2003-10-01

Family

ID=4154382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932094T Expired - Lifetime ES2192205T3 (es) 1994-09-22 1995-09-22 Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.

Country Status (12)

Country Link
EP (1) EP0782441B1 (es)
JP (1) JPH10506388A (es)
CN (1) CN1213742C (es)
AT (1) ATE233551T1 (es)
AU (1) AU3528195A (es)
CA (1) CA2132690A1 (es)
DE (1) DE69529831T2 (es)
DK (1) DK0782441T3 (es)
ES (1) ES2192205T3 (es)
NZ (1) NZ292963A (es)
PT (1) PT782441E (es)
WO (1) WO1996009038A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ES2257858T3 (es) 1998-04-24 2006-08-01 Duke University Porfirinas sustituidas.
JP2003500335A (ja) 1998-12-17 2003-01-07 サングスタット メディカル コーポレイション ヘムオキシゲナーゼ活性の調節による移植片の生存を強化する方法
EP1616869B1 (en) 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
EP1439842A4 (en) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
CN1646140A (zh) 2002-02-04 2005-07-27 阿尔法玛药品研发有限公司 可释放co的化合物在用于治疗炎症药物的制备中的应用
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
EP1940425A4 (en) * 2005-09-30 2010-02-03 Ovation Pharmaceuticals Inc METHOD FOR THE TREATMENT OF PANCREATITIS
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
AU2011218316B2 (en) * 2010-02-18 2015-08-20 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
CN105727379A (zh) * 2016-02-25 2016-07-06 顾宇春 血红素加氧酶药物洗脱支架
CN110585215B (zh) * 2019-09-19 2023-06-02 中山大学 氯化血红素及其复合物在医药中的新应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
DE69229598T2 (de) * 1991-04-19 1999-11-04 Childrens Medical Center Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
CA2119572C (en) * 1991-09-24 2005-07-05 Larry Kay Keefer Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
WO1994013252A1 (en) * 1992-12-10 1994-06-23 Hemogen, Inc. Method for stimulating production of heme oxygenase using vitamin b12

Also Published As

Publication number Publication date
AU3528195A (en) 1996-04-09
WO1996009038A2 (en) 1996-03-28
CN1213742C (zh) 2005-08-10
NZ292963A (en) 2001-06-29
DK0782441T3 (da) 2003-06-30
CA2132690A1 (en) 1996-03-23
ATE233551T1 (de) 2003-03-15
EP0782441A1 (en) 1997-07-09
CN1166785A (zh) 1997-12-03
DE69529831D1 (de) 2003-04-10
EP0782441B1 (en) 2003-03-05
PT782441E (pt) 2003-07-31
DE69529831T2 (de) 2003-12-24
JPH10506388A (ja) 1998-06-23
WO1996009038A3 (en) 1996-06-13

Similar Documents

Publication Publication Date Title
ES2192205T3 (es) Uso de un compuesto que aumenta la actividad o la cantidad de hemooxigenasa (ho) en un mamifero.
ATE135231T1 (de) Verwendung von ''cartilage-inducing factor'' (cif) zur behandlung von hemato- oder lymphopoietischen krankheiten
CA2105529A1 (en) Composition comprising non-steroidal anti-inflammatory agent and effectively non-antibacterial tetracycline
CA2031368A1 (en) Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline
DE19975031I2 (de) Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.
NL930005I2 (nl) 17 Beta-gesubstitueerde-4-aza-5alfa-androstenonen en gebruik ervan als inhibitoren van 5alfa-reduct ase.
DE69738693D1 (de) On wunden- und brandheilung
IT8519382A0 (it) Composizioni analgesiche e antiinfiammatorie comprendenti difeni dramina e metodi di usare le stesse
IT8123988A0 (it) Impiego della combinazione di un inibitore della aromatasi con un antiandrogeno per la profilassi ela terapia dell'iperplasia della prostata.
ES2187560T3 (es) Dentifrico antiseptico.
ES2160892T3 (es) Uso de una mezcla de tensioactivos para inhibir la corrosion.
ES2138940T1 (es) Quelactantes de plata del acido etilendiamintriacetico y del acido n-acil etilendiamintriacetico.
EP0751954A4 (en) ANTI-INFLAMMATION COMPOSITION AND METHOD IN WHICH DES-TYR DYNORPHINE AND ANALOGUE ARE USED
ATE195528T1 (de) Steroidnitritesterderivate und ihre verwendung als entzündungshemmende medikamente
SV1994000076A (es) Derivados de acido n-acetil neuraminico cristalino y su preparacion ref. 1123a/sv
ES2094267T3 (es) Utilizacion de micelio de hongos como agente auxiliar para suelos.
ES2086471T3 (es) Medio para la proteccion temporal contra el oscurecimiento de superficies de plata y superficies de cobre desnudas y procedimiento para su utilizacion.
MY106885A (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
ES2161293T3 (es) Derivados de enol acilados como profarmacos de inhibidores de la elastasa.
WO1998047494A3 (en) Novel use of matrix metalloproteinase inhibitors
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
ITMI911439A1 (it) Composizione farmaceutica ad uso topico per il trattamento di cicatrizzazione e riepitelizzazione di ulcere flebostatiche croniche